logo

Oncosec Medical Inc (ONCS)



Trade ONCS now with
  Date
  Headline
6/14/2021 8:32:05 AM OncoSec Appoints Jeffrey Silverman As VP Of Product Engineering
5/17/2021 8:35:54 AM OncoSec Appoints Robert Schinagl As VP Of Program And Alliance Management
3/1/2021 9:04:59 AM ONCS : TAVO Therapy Safe And Effective At Increasing Tumor Antigen Specific Presentation & Recruitment Of CD8+ T Cells
2/18/2021 8:32:51 AM OncoSec Appoints Bridget O'Keeffe As VP Of Clinical Development
1/27/2021 9:19:16 AM OncoSec Announces First Subjects Dosed In Phase 1 Trial Of CORVax12, COVID-19 Vaccine Candidate
1/25/2021 4:12:06 PM OncoSec Medical Closes $42.0 Mln Public Offering Of Common Stock
1/21/2021 8:37:38 AM OncoSec Medical Prices Public Offering Of 7.71 Mln Shares At $5.45 Per Share
1/19/2021 8:41:02 AM OncoSec Reaches Option Deal With Sirtex Medical To Co-Promote TAVO
1/8/2021 9:02:28 AM OncoSec Says First Patient Dosed In Phase 2 Trial Of TAVO Plus OPDIVO As Neoadjuvant Therapy For Melanoma
12/3/2020 9:08:21 AM OncoSec Reports Publication In International Journal Of Surgery Case Reports
11/24/2020 9:06:07 AM OncoSec Announces License Agreement For Cliniporator Gene Electrotransfer Platform Developed By IGEA
11/18/2020 9:08:38 AM OncoSec Announces KEYNOTE-695 Reaches Full Enrollment
11/9/2020 8:43:26 AM OncoSec Announces Positive Interim Data From KEYNOTE-695 Trial In Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
11/5/2020 9:03:21 AM OncoSec Medical Reports Positive KEYNOTE-695 Data In Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
11/3/2020 9:02:05 AM OncoSec To Present Positive Interim Data From KEYNOTE-695 Trial In Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
10/29/2020 9:21:50 AM OncoSec Medical Says FDA Approved IND Application For First-in-human Phase 1 Trial For CORVax12